Neurobiological Technologies, Inc. (Nasdaq: NTIID)
2007年9月19日 - 11:35PM
PRニュース・ワイアー (英語)
Q4/07 Review Issued by Scimitar Equity Research, Inc. BOSTON, Sept.
19 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues
a review of Neurobiological Technologies, Inc. (NASDAQ:NTIID),
entitled, "The Secret of Success is Constancy of Purpose:
VIPRINEX(TM) Could Restore Stroke Patients to Fuller Lives and They
Will Be the Real Miracle of NTII's Achievement". This review is
available at our website: http://www.scimitarequity.com/.
Neurobiological Technologies, Inc. (NTII) is a biotechnology
company engaged in the business of acquiring and developing central
nervous system related drug candidates. NTIID is focused on
therapies for neurological conditions that occur in connection with
ischemic stroke, brain cancer, Alzheimer's disease and dementia.
NTIID's strategy is to in-license and develop later-stage drug
candidates that target major medical needs and that can be rapidly
commercialized. NTIID's experienced management team oversees the
human clinical trials necessary to establish preliminary evidence
of efficacy. For further information, please visit NTII's website
at http://www.ntii.com/. NTII's common stock will trade under the
symbol "NTIID" for 20 trading days to denote the recent reverse (7
for 1) split. After that time, the symbol will revert back to
"NTII". Holders of record will be receiving instructions from
NTII's transfer agent to define the procedures of surrendering
their pre-split share certificates as well as assign their receipt
of the new post-split certificates. NTIID's primary objective in
authorizing the reverse split is to raise the share trading price
of its common stock and to increase the number of shares of
authorized but un-issued common stock. Scimitar Equity Research,
Inc. provides sponsored equity research of the health sciences
industry for the institutional and investment communities. We
certify that all the views expressed in this review, accurately
reflect our personal views about NTIID (Nasdaq) and its or their
securities. No part of our compensation was, is, or will be,
directly or indirectly, related to the specific recommendations or
views contained in this review and we will not have any investment
banking relationships or personal investment in any sponsored
company. Investors are advised that this analysis and review is
issued solely for informational purposes and is not to be construed
as an offer to sell or the solicitation of an offer to buy.
Scimitar was paid for preparing this review. This analysis and
review does not have regard to the specific investment objectives,
financial situation and the information contained herein is based
on sources that we believe to be reliable but is not guaranteed by
us as being accurate and does not purport to be a complete
statement or summary of the available data. Any opinions expressed
are statements of our own judgment as of the date of publication
and are subject to change without notice. Please read all our
important disclosures. CONTACT: Scimitar Equity Research, Inc.
Henry W. McCusker Director of Research phone: (617) 559.1080 fax:
(617) 559.1083 e-mail: DATASOURCE: Scimitar Equity Research, Inc.
CONTACT: Henry W. McCusker, Director of Research, of Scimitar
Equity Research, Inc., +1-617-559-1080, fax: +1-617-559-1083, Web
site: http://www.scimitarequity.com/ http://www.ntii.com/
Copyright
Neurobiological Technologies (MM) (NASDAQ:NTIID)
過去 株価チャート
から 5 2024 まで 6 2024
Neurobiological Technologies (MM) (NASDAQ:NTIID)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Neurobiological Technologies (MM) (ナスダック市場): 0 recent articles
その他のNeurobiological Technologies (MM)ニュース記事